ILMN

Illumina is expected to report Q3 2026 earnings on October 29 with consensus estimates of $1.38 EPS (+3% YoY) and $1.14B revenue (+5% YoY). The company has a positive Earnings ESP of +9.16% combined with a Zacks Rank #2, suggesting a likely earnings beat. Illumina has beaten consensus EPS estimates in all four of the last quarters.

The article explains how to identify medical stocks positioned for positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter. It demonstrates that combining positive ESP with a Zacks Rank #3 or better has historically resulted in positive earnings surprises 70% of the time with 28.3% average annual returns. Two medical stocks are highlighted as examples: Illumina with a +9.16% ESP and Buy rating, and Vertex Pharmaceuticals with a +4.98% ESP and Hold rating.

Illumina is positioned to potentially beat earnings estimates in its next quarterly report on October 29, 2026. The company has a strong track record of beating estimates, with an average surprise of 8.01% over the last two quarters. With a positive Earnings ESP of +9.16% and a Zacks Rank #2 (Buy), analysts have recently become bullish on the company's earnings prospects.

Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption.

PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%.

The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.

Grail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026.

An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.

Illumina is developing an AI strategy centered on biological data from its sequencing technology. The company's initiatives, including the Billion Cell Atlas and expanded drugmaker partnerships, could create a new growth engine if it successfully converts its scientific advantages into recurring commercial revenue.

A comparison of two Medical-Biomedical and Genetics stocks reveals that Regeneron (REGN) presents a better value opportunity than Illumina (ILMN) for value investors. REGN has a stronger Zacks Rank of #1 (Strong Buy) versus ILMN's #2 (Buy), along with significantly more attractive valuation metrics including a forward P/E of 14.16 versus ILMN's 50.77, and a PEG ratio of 1.23 versus 3.85.

The global single cell sequencing market is estimated at USD 1.38 billion and is projected to expand at a 15% CAGR through 2035, driven by advances in genomics, declining sequencing costs, and wider adoption in drug discovery, diagnostics, and precision medicine. North America is expected to account for approximately 50% of the market, with academic institutions representing the largest end-user segment at 60%. Key challenges include data processing requirements, quality management, and workflow costs.

The Invesco S&P MidCap Quality ETF (XMHQ) offers broad exposure to mid-cap blend stocks with $5.46 billion in assets and a competitive 0.25% expense ratio. The ETF has returned 11.95% year-to-date and 12.26% over the past year, with heavy allocation to Industrials (29.4%). It holds a Zacks ETF Rank of 2 (Buy), though larger competitors like Vanguard Morningstar Mid-Cap ETF and iShares Core S&P Mid-Cap ETF offer lower expense ratios.

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.